Welcome to CDC Stacks | Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. - 7448 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.
Filetype[PDF - 1.59 MB]


Details:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.
    Published:
    March 12, 2010
    Source:
    MMWR. Morbidity and mortality weekly report. 2010; 59(9):258-61.
    Description:
    On February 24, 2010, a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.]) was licensed by the Food and Drug Administration (FDA) for prevention of invasive pneumococcal disease (IPD...
    Status:
    superseded
    File Type:
    Filetype[PDF - 1.59 MB]
  2. Licensure of a Meningococcal Conjugate Vaccine for Children Aged 2 Through 10 Years and Updated Booster Dose Guidance for Adolescents and Other Persons at Increased Risk for Meningococcal Disease - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR 2011; 60 (30):1018-1019.
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.
    Published:
    August 11, 2011
    Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(30):1018-9.
    Description:
    In January 2011, the Food and Drug Administration lowered the approval age range for use of MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics), a quadrivalent meningococcal conjugate vaccine, to include persons aged 2 through 55 years. One other...
    Status:
    superseded
    File Type:
    Filetype[PDF - 72.15 KB]
  3. Updated Recommendations for Use of Meningococcal Conjugate Vaccines -- Advisory Committee on Immunization Practices (ACIP), 2010
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.
    Published:
    January 28, 2011
    Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(3):72-6.
    Description:
    On October 27, 2010, the Advisory Committee on Immunization Practices (ACIP) approved updated recommendations for the use of quadrivalent (serogroups A, C, Y, and W-135) meningococcal conjugate vaccines (Menveo, Novartis; and Menactra, Sanofi Pasteur...
    Status:
    superseded
    File Type:
    Filetype[HTML]
  4. FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP)
    Published:
    May 28, 2010
    Source:
    MMWR. Morbidity and mortality weekly report. 2010; 59(20):630-2.
    Description:
    To develop the 1993 Sexually Transmitted Diseases Treatment Guidelines, experts from the Centers for Disease Control and Prevention reviewed the literature on sexually transmitted disease treatment, assembled tables of evidence, and listed key questi...
    Status:
    superseded
    File Type:
    Filetype[PDF]
  5. Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Personal Author:
    Zangwill, Kenneth M. ; Wenger, Jay D. ; Sutter, Roland W. ; Hadler, Stephen C. ;
    Corporate Author:
    Centers for Disease Control (U.S.). Immunization Practices Advisory Committee. ; National Center for Infectious Diseases (U.S.); National Center for Prevention Services (U.S.);
    Published:
    September 17, 1993
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 1993; 42(RR-13):1-15.
    Description:
    These recommendations include information on two vaccines recently licensed for use among infants: Haemophilus b Conjugate Vaccine (PRP-T [ActHIB, OmniHIB]), manufactured by Pasteur M rieux Vaccins, and TETRAMUNE, manufactured by Lederle Laboratories...
    Status:
    current
    File Type:
    Filetype[PDF - 221.63 KB]